Latest:
It’s Time to Address Patient Needs: The Changing Landscape of Colorectal Cancer Treatment
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jessica Paulus, ScD
Jessica Paulus, ScD, is the senior director of Observational Research at Ontada.
Latest:
Paulus on Research With a Real-World External Control Arm in HER2+ Breast Cancer
Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.
Richard Burkhart, MD
Latest:
Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Ongoing Research
In this seventh episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, discuss ongoing research such as the PASS-01 trial (NCT04469556) in pancreatic cancer and ways to translate advances in the metastatic setting to the curative setting.
Terufumi Kato, MD
Latest:
Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC
Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.
Lance C. Pagliaro, MD
Latest:
Dr Pagliaro on the Use of First-Line Avelumab Maintenance Therapy in Urothelial Carcinoma
Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.
Amitkumar Mehta, MD
Latest:
Evolving First-Line Standards and the Foundation of Follicular Lymphoma Care
This segment outlines how clinicians today approach initial management, recognizing that improved survival and expanding treatment choices have dramatically changed the patient journey. As Mehta and Bailey note, frontline success does not eliminate the likelihood of relapse, making it essential to anticipate how early decisions may influence subsequent therapeutic sequencing.
Daniel J. Hausrath, MD
Latest:
The Podcast by Fellows for Fellows
Daniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.
